Literature DB >> 15294875

Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status.

Carla Oliveira1, Jantine L Westra, Diego Arango, Miina Ollikainen, Enric Domingo, Ana Ferreira, Sérgia Velho, Renee Niessen, Kristina Lagerstedt, Pia Alhopuro, Paivi Laiho, Isabel Veiga, Manuel R Teixeira, Marjolijn Ligtenberg, Jan H Kleibeuker, Rolf H Sijmons, John T Plukker, Kohzoh Imai, Pedro Lage, Richard Hamelin, Cristina Albuquerque, Simo Schwartz, Annika Lindblom, Päivi Peltomaki, Hiroyuki Yamamoto, Lauri A Aaltonen, Raquel Seruca, Robert M W Hofstra.   

Abstract

In sporadic colorectal tumours the BRAFV600E is associated with microsatellite instability (MSI-H) and inversely associated to KRAS mutations. Tumours from hereditary non-polyposis colorectal cancer (HNPCC) patients carrying germline mutations in hMSH2 or hMLH1 do not show BRAFV600E, however no consistent data exist regarding KRAS mutation frequency and spectrum in HNPCC tumours. We investigated KRAS in 158 HNPCC tumours from patients with germline hMLH1, hMSH2 or hMSH6 mutations, 166 MSI-H and 688 microsatellite stable (MSS) sporadic carcinomas. All tumours were characterized for MSI and 81 of 166 sporadic MSI-H colorectal cancer (CRCs) were analysed for hMLH1 promoter hypermethylation. KRAS mutations were observed in 40% of HNPCC tumours, and the mutation frequency varied upon the mismatch repair gene affected: 48% (29/61) in hMSH2, 32% (29/91) in hMLH1 and 83% (5/6) in hMSH6 (P = 0.01). KRAS mutation frequency was different between HNPCC, MSS and MSI-H CRCs (P = 0.002), and MSI-H with hMLH1 hypermethylation (P = 0.005). Furthermore, HNPCC CRCs had more G13D mutations than MSS (P < 0.0001), MSI-H (P = 0.02) or MSI-H tumours with hMLH1 hypermethylation (P = 0.03). HNPCC colorectal and sporadic MSI-H tumours without hMLH1 hypermethylation shared similar KRAS mutation frequency, in particular G13D. In conclusion, we show that depending on the genetic/epigenetic mechanism leading to MSI-H, the outcome in terms of oncogenic activation may be different, reinforcing the idea that HNPCC, sporadic MSI-H (depending on the hMLH1 status) and MSS CRCs, may target distinct kinases within the RAS/RAF/MAPK pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15294875     DOI: 10.1093/hmg/ddh238

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  47 in total

1.  KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).

Authors:  Harry H Yoon; David Tougeron; Qian Shi; Steven R Alberts; Michelle R Mahoney; Garth D Nelson; Suresh G Nair; Stephen N Thibodeau; Richard M Goldberg; Daniel J Sargent; Frank A Sinicrope
Journal:  Clin Cancer Res       Date:  2014-03-31       Impact factor: 12.531

2.  Therapeutic Response of Metastatic Colorectal Cancer Harboring a KRAS Missense Mutation After Combination Chemotherapy With the EGFR Inhibitor Panitumumab.

Authors:  Emil Lou; Donna D'Souza; Andrew C Nelson
Journal:  J Natl Compr Canc Netw       Date:  2017-04       Impact factor: 11.908

3.  The CpG island methylator phenotype in colorectal cancer.

Authors:  Wade S Samowitz
Journal:  J Mol Diagn       Date:  2007-07       Impact factor: 5.568

Review 4.  KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.

Authors:  J H J M van Krieken; A Jung; T Kirchner; F Carneiro; R Seruca; F T Bosman; P Quirke; J F Fléjou; T Plato Hansen; G de Hertogh; P Jares; C Langner; G Hoefler; M Ligtenberg; D Tiniakos; S Tejpar; G Bevilacqua; A Ensari
Journal:  Virchows Arch       Date:  2008-09-18       Impact factor: 4.064

5.  Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling.

Authors:  Toshinori Hinoue; Daniel J Weisenberger; Fei Pan; Mihaela Campan; Myungjin Kim; Joanne Young; Vicki L Whitehall; Barbara A Leggett; Peter W Laird
Journal:  PLoS One       Date:  2009-12-21       Impact factor: 3.240

6.  Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications.

Authors:  Athanasios C Tsiatis; Alexis Norris-Kirby; Roy G Rich; Michael J Hafez; Christopher D Gocke; James R Eshleman; Kathleen M Murphy
Journal:  J Mol Diagn       Date:  2010-04-29       Impact factor: 5.568

7.  Ligase detection reaction for the analysis of point mutations using free-solution conjugate electrophoresis in a polymer microfluidic device.

Authors:  Rondedrick Sinville; Jennifer Coyne; Robert J Meagher; Yu-Wei Cheng; Francis Barany; Annelise Barron; Steven A Soper
Journal:  Electrophoresis       Date:  2008-12       Impact factor: 3.535

8.  Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.

Authors:  Allison M Cushman-Vokoun; Daniel G Stover; Zhiguo Zhao; Elizabeth A Koehler; Jordan D Berlin; Cindy L Vnencak-Jones
Journal:  Clin Colorectal Cancer       Date:  2013-06-14       Impact factor: 4.481

9.  Colorectal carcinomas in MUTYH-associated polyposis display histopathological similarities to microsatellite unstable carcinomas.

Authors:  Maartje Nielsen; Noel F C C de Miranda; Marjo van Puijenbroek; Ekaterina S Jordanova; Anneke Middeldorp; Tom van Wezel; Ronald van Eijk; Carli M J Tops; Hans F A Vasen; Frederik J Hes; Hans Morreau
Journal:  BMC Cancer       Date:  2009-06-15       Impact factor: 4.430

10.  Mixed lineage kinase 3 gene mutations in mismatch repair deficient gastrointestinal tumours.

Authors:  Sérgia Velho; Carla Oliveira; Joana Paredes; Sónia Sousa; Marina Leite; Paulo Matos; Fernanda Milanezi; Ana Sofia Ribeiro; Nuno Mendes; Danilo Licastro; Auli Karhu; Maria José Oliveira; Marjolijn Ligtenberg; Richard Hamelin; Fátima Carneiro; Annika Lindblom; Paivi Peltomaki; Sérgio Castedo; Simó Schwartz; Peter Jordan; Lauri A Aaltonen; Robert M W Hofstra; Gianpaolo Suriano; Elia Stupka; Arsenio M Fialho; Raquel Seruca
Journal:  Hum Mol Genet       Date:  2009-12-02       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.